Literature DB >> 9485025

Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation.

M Barthelman1, W Chen, H L Gensler, C Huang, Z Dong, G T Bowden.   

Abstract

The monoterpene perillyl alcohol (POH) has proven efficacious against the formation and progression of a variety of cancers. In this study, we tested the ability of POH to inhibit photocarcinogenesis in a nonmelanoma model of mouse skin carcinogenesis and its ability to inhibit UVB-induced activator protein 1 (AP-1) transactivation in mouse skin and human keratinocytes. POH (10 mM) was applied topically to the ears and shaved dorsal surface of groups of 35 BALB/c mice throughout the experiment, during and after UVB treatment. Topical POH significantly inhibited tumor incidence and multiplicity, average tumor size, and the average tumor burden/mouse without any apparent toxicity. POH inhibited UVB-induced AP-1 transactivation in both cultured human keratinocytes and transgenic mice that stably express a luciferase reporter driven by AP-1 elements. The results suggest that POH might be used for chemoprevention of human skin cancer, and that inhibition of AP-1 activity is functionally related to inhibition of skin carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

Review 2.  Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 3.  Molecular and cellular targets.

Authors:  Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

4.  Repeated short-term stress synergizes the ROS signalling through up regulation of NFkB and iNOS expression induced due to combined exposure of trichloroethylene and UVB rays.

Authors:  Farrah Ali; Sarwat Sultana
Journal:  Mol Cell Biochem       Date:  2011-09-27       Impact factor: 3.396

5.  Chitooligosaccharides attenuate UVB-induced damages in human dermal fibroblasts.

Authors:  Byul-Nim Ahn; Jung-Ae Kim; S W A Himaya; Soon-Sun Bak; Chang-Suk Kong; Se-Kwon Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

6.  Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin.

Authors:  Jaroslav Janda; Nichole B Burkett; Karen Blohm-Mangone; Vivian Huang; Clara Curiel-Lewandrowski; David S Alberts; Emanuel F Petricoin; Valerie S Calvert; Janine Einspahr; Zigang Dong; Ann M Bode; Georg T Wondrak; Sally E Dickinson
Journal:  Photochem Photobiol       Date:  2016-12-08       Impact factor: 3.421

Review 7.  The molecular basis that unifies the metabolism, cellular uptake and chemopreventive activities of dietary isothiocyanates.

Authors:  Yuesheng Zhang
Journal:  Carcinogenesis       Date:  2011-11-10       Impact factor: 4.944

8.  Stability of sulforaphane for topical formulation.

Authors:  Stephen J Franklin; Sally E Dickinson; Kelly L Karlage; G T Bowden; Paul B Myrdal
Journal:  Drug Dev Ind Pharm       Date:  2013-04-23       Impact factor: 3.225

Review 9.  Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis.

Authors:  S J Cooper; G T Bowden
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

10.  Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer.

Authors:  Sally E Dickinson; Tania F Melton; Erik R Olson; Jian Zhang; Kathylynn Saboda; G Timothy Bowden
Journal:  Cancer Res       Date:  2009-08-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.